Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARITIME-T2D-3: Maridebart Cafraglutide vs Semaglutide in Type 2 Diabetes
NCT07866066Phase 3Not yet recruiting
- Sponsor
- Amgen
- Start
- Nov 2026
- Primary completion
- Sep 2028
01
Overview
A Phase 3 trial of maridebart cafraglutide in type 2 diabetes mellitus (T2DM), sponsored by Amgen. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07866066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07866066.